



**NHS Berkshire West Area Prescribing Committee**  
**Minutes of Meeting held on 3 July 2013**  
**Room G29/30, 57/59 Bath Road, Reading, RG30 2BA**

**Attendance:**



**1. Chairman's Introduction**

█ welcomed everyone to the meeting.

**2. Apologies**

█.

**3. Pecuniary Interests**

█ mentioned that she had attended an Advisory Board for Shire commissioned by Pharmacy Management.

**4. Minutes of the EPC meeting held on 1<sup>st</sup> May 2013**

The minutes were agreed as accurate.

**5. Matters Arising not Included in Main Items**

**5.1 APC Terms of Reference**

Amendments to the Terms of Reference were discussed:

- The '\*' in the Mission Statement needs definition added.
- Reference to NPSA and National Commissioning Board to be removed.
- Audits completed by the Medicines Optimisation Team need to come to APC annually.
- Patients Groups need to be added to the 'Topic Selection' paragraph.
- NICE Guidance states that public engagement / consultation needs to be included, 'Needs of the Community' paragraph needs to be amended to



include this. [REDACTED] to draft wording for this.

- [REDACTED] suggested that wording was included that agreement was made with other Trusts in the area when policy agreed.

[REDACTED] suggested that to speed up the decision making process, she would draft policies for each option for topics and these would be sent out with the papers, therefore when the decision is made the relevant policy wording could be agreed at the same meeting. This policy would then be ratified at the next GPs MMC meeting instead of having to come back to the next APC meeting first. The group agreed this would be a good idea.

It was also suggested that when papers are sent for comment, the email should also ask that people reply with 'no comment' if this is their response.

[REDACTED] has now joined the group as a Lay Member and [REDACTED] may have another person to take on this role shortly.

5.3 EPC 12/40 Melatonin for the treatment of sleep disorders in paediatric patients – [REDACTED] is still working on this.

5.8 Ketamin for Refractory Pain: shared Care Protocol – [REDACTED] is working on this.

## 6. **Horizon Scanning / NICE**

[REDACTED] will circulate the list of topics to the group.

## 7. **NICE Medical Innovation Briefings (Medtech Briefings) / The Health Technologies Adoption Programme (HTAP)**

New Medtech bulletins will be issued and [REDACTED] will incorporate into papers where appropriate.

## 8. **Future Topics / preventing duplication of formulary submissions**

[REDACTED] circulated a template and suggested that this was used by all Trusts for topic submissions.

[REDACTED] and [REDACTED] would discuss outside the meeting and speak to [REDACTED] at the RBH.

## 9. **Existing and Expired EPC Topics**

[REDACTED] have looked at the list and asked if the group was happy that if nothing has changed with a topic it is re-issued with new date. It was agreed that the group should be made aware of these policies but happy that papers can be renewed in this way.

## 10. **Policies Agreed at Meeting Held on 1<sup>st</sup> May 2013**

|         |   |
|---------|---|
| APC 001 | Ulipristal (Esmya®) for uterine fibroids - Approved.        |
| APC 002 | Lixisenatide (Lyxumia®) for type 2 diabetes - Approved      |
| APC 003 | Insulin degludec (Tresiba®) - Approved                      |
| APC 004 | Octasa MR as the first line oral 5-aminosalicylate - Agreed |

**Action: Policies to be submitted to GP's MMC for approval before publishing on Internet.**

## 11. **Papers**

### 11.1 **APC 13/05**



### **New Oral Anticoagulants (NOACs) for stroke prevention in Atrial Fibrillation**

Following discussion at the last meeting the group agreed the amended document.

**Action: Policy to be prepared and emailed to APC members for approval before taken to GP's Medicines Management Committee.**

#### **11.2 APC 13/06**

##### **Berkshire West Diabetes Formulary**

The Berkshire West Diabetes Network were keen for a formulary to be developed for use in Primary Care and asked the Medicines Optimisation Team to produce this.

The group was concerned that the document did not contain evidence. ■ will include this information in the document and bring to the next APC meeting.

Action: ■ to include evidence in document and bring to next meeting.

#### **11.3 APC 13/07**

##### **Ingenol Mebutate**

RBH Dermatologists are keen to use this. Advantage is it is a 3 day treatment rather than several weeks as with other products. No evidence that it prevents SCC / BCC.

Recommendation:

Ingenol is not recommended for prescribing.

**Action: Policy to be prepared and emailed to APC members for approval before taken to GP's Medicines Management Committee.**

#### **11.4 APC 13/08**

##### **Linaclotide for IBS-C**

- New drug
- No details of cost impact for Berkshire included
- Could be used for extreme cases that have been referred to secondary care.

Recommendation:

Linaclotide should be a treatment option for a subgroup of patients referred to secondary care.

**Action: Policy to be prepared and emailed to APC members for approval before taken to GP's Medicines Management Committee. Review in one year.**

#### **11.5 APC 13/09**

##### **Zonisamide**

- Red drug

Recommendation:

Zonisamide should be a treatment option for a small subgroup of patients seen in secondary care who are not able to tolerate or take anti-epileptic medication as advised in NICE clinical guidance.

**Action: Policy to be prepared and emailed to APC members for approval before taken to GP's Medicines Management Committee.**



#### 11.6 APC 13/10

##### **Lisdexamphetamine for ADHD**

- Currently licensed for children but not adults in UK.
- Risk of overdose needs to be included in Shared Care Protocol.
- Not CD at the moment but will become.
- Work needs to be done on prescribing arrangements for ADHD in Children – [REDACTED] will do this.

##### **Recommendation:**

Lisdexamphetamine should be a treatment option for the management of ADHD when previous response to methylphenidate in a subgroup of patients is considered inadequate.

##### **Action:**

- [REDACTED] to look at prescribing arrangements for ADHD in children.
- **Policy to be prepared and emailed to APC members for approval before taken to GP's Medicines Management Committee.**

#### 11.7 APC 13/11

##### **TA280: Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234)**

For APC to note.

[REDACTED] to clarify pathway in secondary care.

**Action: Policy to be prepared and emailed to APC members for approval before taken to GP's Medicines Management Committee.**

#### 11.8 APC 13/12

##### **Betmiga™ (mirabegron) prolonged-release tablets**

NICE guidance is now available.

[REDACTED] at RBH has submitted request to DTC for this to be included on formulary.

Could be used as 3<sup>rd</sup> line option.

No information of effectiveness included in paper.

Some concerns about its increased use in the elderly.

[REDACTED] to produce a simple protocol and bring to next meeting.

**Action: [REDACTED] to produce a simple protocol and bring to next meeting.**

#### 11.9 APC 13/13

TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

Approved by NICE

[REDACTED] working on pathway and will bring to next meeting.



**Action:** ■ to bring pathway to next meeting.

**12. Any Other Business**

■ advised that NICE are now recommending Tamoxifen for breast cancer prevention and the Trust needed to look at how this cost was managed. It was felt this was something for Specialised Commissioning to look at.

■ suggested that an APC email account be set up so it was easier to identify emails relating to this group. ■ to look into setting this up.

■ asked if data collected on a particular drug should come to APC and it was agreed this should happen and if necessary the policy should be reviewed.

**Dates of Future Meetings**

| <b>Date of Meeting</b>             | <b>Venue</b>                                    |
|------------------------------------|---|
| Wed 4 <sup>th</sup> September 2013 | Room G29/30, 57/59 Bath Road, Reading, RG30 2BA |
| Wed 6 <sup>th</sup> November 2013  | Room G29/30, 57/59 Bath Road, Reading, RG30 2BA |
| Wed 8 <sup>th</sup> January 2014   | Room G29/30, 57/59 Bath Road, Reading, RG30 2BA |
| Wed 5 <sup>th</sup> March 2014     | Room G29/30, 57/59 Bath Road, Reading, RG30 2BA |

All Meetings 10.00am – 12.00pm